Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amatuximab + cisplatin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Eisai
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of amatuximab (a chimeric IgG1 monoclonal antibody targeting mesothelin), cisplatin (a platinum-based chemotherapy agent), and pemetrexed (a folate analog). The combination targets mesothelin-expressing cancers, particularly malignant pleural mesothelioma. Amatuximab works by binding to mesothelin, blocking its interaction with CA125/MUC16, and triggering antibody-dependent cellular cytotoxicity (ADCC). This prevents cell adhesion, migration patterns, and metastasis. Pemetrexed inhibits multiple enzymes involved in folate metabolism and DNA synthesis, while cisplatin acts as a platinum-based chemotherapeutic agent.
- Other names
- amatuximab + pemetrexed + cisplatin
02
Targets
DNADHFR (Dihydrofolate reductase)MesothelinTS (Thymidylate synthase)MUC16 (Mucin-16)
Beyond the preview
Go deeper on amatuximab + cisplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amatuximab + cisplatin + pemetrexed.